{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:37:24Z","timestamp":1780619844933,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T00:00:00Z","timestamp":1512691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T00:00:00Z","timestamp":1512691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polycythemia vera (PV) and essential thrombocythemia (ET) are Philadelphia-negative myeloproliferative neoplasms (MPNs) characterized by erythrocytosis and thrombocytosis, respectively. Approximately 95% of PV and 50\u201370% of ET patients harbor the V617F mutation in the exon 14 of <jats:italic>JAK2<\/jats:italic> gene, while about 20\u201330% of ET patients carry CALRins5 or CALRdel52 mutations. These ET CALR-mutated subjects show higher platelet count and lower thrombotic risk compared to JAK2-mutated patients. Here, we showed that CALR-mutated and JAK2V617F-positive CD34+ cells display different gene and miRNA expression profiles. Indeed, we highlighted several pathways differentially activated between JAK2V617F- and CALR-mutated progenitors, i.e., mTOR, MAPK\/PI3K, and MYC pathways. Furthermore, we unveiled that the expression of several genes involved in DNA repair, chromatin remodeling, splicing, and chromatid cohesion are decreased in CALR-mutated cells. According to the low risk of thrombosis in CALR-mutated patients, we also found the downregulation of several genes involved in thrombin signaling and platelet activation. As a whole, these data support the model that CALR-mutated ET could be considered as a distinct disease entity from JAK2V617F-positive MPNs and may provide the molecular basis supporting the different clinical features of these patients.<\/jats:p>","DOI":"10.1038\/s41408-017-0010-2","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T11:28:26Z","timestamp":1512473306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles"],"prefix":"10.1038","volume":"7","author":[{"given":"Roberta","family":"Zini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-284X","authenticated-orcid":false,"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pietra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Rumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Rontauroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Salati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Tagliafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0660-6110","authenticated-orcid":false,"given":"Rossella","family":"Manfredini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,8]]},"reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi, A. & Vardiman, J. W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia \n                           22, 14\u201322 (2008).","journal-title":"Leukemia"},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.blre.2016.06.001","volume":"30","author":"T Barbui","year":"2016","unstructured":"Barbui, T. et al. The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances. Blood Rev. \n                           30, 453\u2013459 (2016).","journal-title":"Blood Rev."},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ajh.23135","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi, A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. \n                           87, 285\u2013293 (2012).","journal-title":"Am. J. Hematol."},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/ajh.24607","volume":"92","author":"A Tefferi","year":"2017","unstructured":"Tefferi, A. & Barbui, T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 92, 94\u2013108 (2017).","journal-title":"Am. J. Hematol"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature \n                           434, 1144\u20131148 (2005).","journal-title":"Nature"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Eng. J. Med. \n                           352, 1779\u20131790 (2005).","journal-title":"N. Eng. J. Med."},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani, A. D. et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood \n                           108, 3472\u20133476 (2006).","journal-title":"Blood"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl, T. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Eng. J. Med. \n                           369, 2379\u20132390 (2013).","journal-title":"N. Eng. J. Med."},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia, J. et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Eng. J. Med. \n                           369, 2391\u20132405 (2013).","journal-title":"N. Eng. J. Med."},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi, A. et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood \n                           124, 2507\u20132513; quiz 615 (2014).","journal-title":"Blood"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi, A. et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia \n                           28, 1472\u20131477 (2014).","journal-title":"Leukemia"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1038\/leu.2014.148","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi, A. et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia \n                           28, 2300\u20132303 (2014).","journal-title":"Leukemia"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi, E. et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood \n                           123, 1544\u20131551 (2014).","journal-title":"Blood"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno, G. et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood \n                           123, 1552\u20131555 (2014).","journal-title":"Blood"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","volume":"127","author":"I Chachoua","year":"2016","unstructured":"Chachoua, I. et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood \n                           127, 1325\u20131335 (2016).","journal-title":"Blood"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","volume":"127","author":"M Araki","year":"2016","unstructured":"Araki, M. et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood \n                           127, 1307\u20131316 (2016).","journal-title":"Blood"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","volume":"127","author":"C Marty","year":"2016","unstructured":"Marty, C. et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood \n                           127, 1317\u20131324 (2016).","journal-title":"Blood"},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman, J. W. et al. The2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood \n                           114, 937\u2013951 (2009).","journal-title":"Blood"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","volume":"114","author":"P Guglielmelli","year":"2009","unstructured":"Guglielmelli, P. et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood \n                           114, 1477\u20131483 (2009).","journal-title":"Blood"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1182\/blood-2013-12-544197","volume":"124","author":"R Norfo","year":"2014","unstructured":"Norfo, R. et al. miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155\/JARID2 axis in abnormal megakaryopoiesis. Blood \n                           124, e21\u201332 (2014).","journal-title":"Blood"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. U.S.A. \n                           102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"10_CR22","doi-asserted-by":"publisher","first-page":"6450","DOI":"10.1158\/0008-5472.CAN-11-0364","volume":"71","author":"T Tsuruta","year":"2011","unstructured":"Tsuruta, T. et al. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res. \n                           71, 6450\u20136462 (2011).","journal-title":"Cancer Res."},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3727\/096504017X14878536973557","volume":"25","author":"S Ge","year":"2017","unstructured":"Ge, S., Wang, D., Kong, Q., Gao, W., Sun, J. Function of MiR-152 as a tumor suppressor in human breast cancer by targeting PIK3CA. Oncol. Res 25, 1363\u20131371 (2017).","journal-title":"Oncol. Res."},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/jmcb\/mjs049","volume":"5","author":"Q Xu","year":"2013","unstructured":"Xu, Q. et al. A regulatory circuit of miR-148a\/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J. Mol. Cell Biol. 5, 3\u201313 (2013).","journal-title":"J. Mol. Cell Biol"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/ijc.28799","volume":"135","author":"Y Yang","year":"2014","unstructured":"Yang, Y. et al. MiR-503 targets PI3K p85 and IKK-beta and suppresses progression of non-small cell lung cancer. Int. J. Cancer \n                           135, 1531\u20131542 (2014).","journal-title":"Int. J. Cancer"},{"key":"10_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0065-x","volume":"31","author":"Y Fan","year":"2014","unstructured":"Fan, Y. et al. Down-regulation of miR-29c in human bladder cancer and the inhibition of proliferation in T24 cell via PI3K-AKT pathway. Med. Oncol. \n                           31, 65 (2014).","journal-title":"Med. Oncol."},{"key":"10_CR27","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3892\/mmr.2017.6705","volume":"16","author":"X Liu","year":"2017","unstructured":"Liu, X., Song, B., Li, S., Wang, N. & Yang, H. Identification and functional analysis of the risk microRNAs associated with cerebral low-grade glioma prognosis. Mol. Med. Rep. \n                           16, 1173\u20131179 (2017).","journal-title":"Mol. Med. Rep."},{"key":"10_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0557-8","volume":"15","author":"Z Nawaz","year":"2016","unstructured":"Nawaz, Z. et al. PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA. Mol Cancer \n                           15, 74 (2016).","journal-title":"Mol Cancer"},{"key":"10_CR29","doi-asserted-by":"publisher","first-page":"e83018","DOI":"10.1371\/journal.pone.0083018","volume":"8","author":"I Lepore","year":"2013","unstructured":"Lepore, I. et al. HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and\/or b. PLoS ONE \n                           8, e83018 (2013).","journal-title":"PLoS ONE"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccr.2014.08.001","volume":"26","author":"RK Schneider","year":"2014","unstructured":"Schneider, R. K. et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell \n                           26, 509\u2013520 (2014).","journal-title":"Cancer Cell"},{"key":"10_CR31","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/leu.2013.80","volume":"27","author":"SN Khan","year":"2013","unstructured":"Khan, S. N. et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia \n                           27, 1301\u20131309 (2013).","journal-title":"Leukemia"},{"key":"10_CR32","doi-asserted-by":"publisher","unstructured":"Harada, T., et al. HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications. Leukemia (2017), https:\/\/doi.org\/10.1038\/leu.2017.144","DOI":"10.1038\/leu.2017.144"},{"key":"10_CR33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cancergen.2014.10.005","volume":"208","author":"M Chopra","year":"2015","unstructured":"Chopra, M. & Bohlander, S. K. Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases. Cancer Genet. \n                           208, 192\u2013205 (2015).","journal-title":"Cancer Genet."},{"key":"10_CR34","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/MOH.0000000000000346","volume":"24","author":"W Yang","year":"2017","unstructured":"Yang, W. & Ernst, P. Distinct functions of histone H3, lysine 4 methyltransferases in normal and malignant hematopoiesis. Curr. Opin. Hematol. 24, 322\u2013328 (2017).","journal-title":"Curr. Opin. Hematol"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/jnci\/djn253","volume":"100","author":"MY Wu","year":"2008","unstructured":"Wu, M. Y., Eldin, K. W. & Beaudet, A. L. Identification of chromatin remodeling genes Arid4a and Arid4b as leukemia suppressor genes. J. Natl Cancer Inst. \n                           100, 1247\u20131259 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"10_CR36","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/leu.2010.288","volume":"25","author":"H Parker","year":"2011","unstructured":"Parker, H. et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia \n                           25, 489\u2013497 (2011).","journal-title":"Leukemia"},{"key":"10_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12185-016-2119-7","volume":"105","author":"C Mazumdar","year":"2017","unstructured":"Mazumdar, C. & Majeti, R. The role of mutations in the cohesin complex in acute myeloid leukemia. Int. J. Hematol. 105, 31\u201336 (2017).","journal-title":"Int. J. Hematol"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/cas.12532","volume":"105","author":"JJ Wong","year":"2014","unstructured":"Wong, J. J., Lau, K. A., Pinello, N. & Rasko, J. E. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia. Cancer Sci. \n                           105, 1457\u20131463 (2014).","journal-title":"Cancer Sci."},{"key":"10_CR39","doi-asserted-by":"publisher","unstructured":"Ruberti, S, et al. Involvement of MAF\/SPP1 axis in the development of bone marrow fibrosis in PMF patients. Leukemia (2017), https:\/\/doi.org\/10.1038\/leu.2017.220.","DOI":"10.1038\/leu.2017.220"},{"key":"10_CR40","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/j.1538-7836.2011.04530.x","volume":"9","author":"S Negrotto","year":"2011","unstructured":"Negrotto, S. et al. Expression and functionality of type I interferon receptor in the megakaryocytic lineage. J. Thromb. Haemost. \n                           9, 2477\u20132485 (2011).","journal-title":"J. Thromb. Haemost."},{"key":"10_CR41","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1038\/leu.2011.220","volume":"25","author":"J Zhang","year":"2011","unstructured":"Zhang, J. et al. Differential requirements for c-Myc in chronic hematopoietic hyperplasia and acute hematopoietic malignancies in Pten-null mice. Leukemia \n                           25, 1857\u20131868 (2011).","journal-title":"Leukemia"},{"key":"10_CR42","doi-asserted-by":"crossref","first-page":"21380","DOI":"10.18632\/oncotarget.15226","volume":"8","author":"S Rontauroli","year":"2017","unstructured":"Rontauroli, S. et al. miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem\/progenitor cells by targeting SOCS6. Oncotarget \n                           8, 21380\u201321397 (2017).","journal-title":"Oncotarget"},{"key":"10_CR43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.bcmd.2013.01.005","volume":"50","author":"P Roy","year":"2013","unstructured":"Roy, P. & Dasgupta, U. B. The microRNA hsa-miR-503 inhibits growth of K562 cell line. Blood Cells Mol. Dis. \n                           50, 271\u2013272 (2013).","journal-title":"Blood Cells Mol. Dis."},{"key":"10_CR44","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/nm.3385","volume":"19","author":"LC Edelstein","year":"2013","unstructured":"Edelstein, L. C. et al. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat. Med. 19, 1609\u20131616 (2013).","journal-title":"Nat. Med"},{"key":"10_CR45","doi-asserted-by":"publisher","first-page":"e99283","DOI":"10.1371\/journal.pone.0099283","volume":"9","author":"GC Jickling","year":"2014","unstructured":"Jickling, G. C. et al. MicroRNA expression in peripheral blood cells following acute ischemic stroke and their predicted gene targets. PLoS ONE \n                           9, e99283 (2014).","journal-title":"PLoS ONE"},{"key":"10_CR46","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.exphem.2012.01.016","volume":"40","author":"T Ikezoe","year":"2012","unstructured":"Ikezoe, T. et al. Thrombomodulin enhances the antifibrinolytic and antileukemic effects of all-trans retinoic acid in acute promyelocytic leukemia cells. Exp. Hematol. 40, 457\u2013465 (2012).","journal-title":"Exp. Hematol"},{"key":"10_CR47","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell, P. J. et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet \n                           366, 1945\u20131953 (2005).","journal-title":"Lancet"},{"key":"10_CR48","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.exphem.2014.08.006","volume":"42","author":"C Hua","year":"2014","unstructured":"Hua, C. et al. Rictor\/mammalian target of rapamycin 2 regulates the development of Notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3. Exp. Hematol. \n                           42, 1031\u20131040 (2014). e1-4.","journal-title":"Exp. Hematol."},{"key":"10_CR49","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.stem.2012.05.026","volume":"11","author":"JA Magee","year":"2012","unstructured":"Magee, J. A. et al. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell \n                           11, 415\u2013428 (2012).","journal-title":"Cell Stem Cell"},{"key":"10_CR50","first-page":"946","volume":"3","author":"X Huang","year":"2004","unstructured":"Huang, X. et al. Physical and functional interactions between mitotic kinases during polyploidization and megakaryocytic differentiation. Cell Cycle \n                           3, 946\u2013951 (2004).","journal-title":"Cell Cycle"},{"key":"10_CR51","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/bjh.13539","volume":"172","author":"JM Torregrosa","year":"2016","unstructured":"Torregrosa, J. M. et al. Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation. Br. J. Haematol. \n                           172, 813\u2013815 (2016).","journal-title":"Br. J. Haematol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0010-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0010-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0010-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T17:31:34Z","timestamp":1671730294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0010-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":51,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1038\/s41408-017-0010-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]},"assertion":[{"value":"28 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s note"}}],"article-number":"638"}}